Cytek Biosciences, Inc. Revenue 2020–2025
Cytek Biosciences, Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Cytek Biosciences, Inc. revenue for the quarter ending March 31, 2026 was 44.1 M, a 6.46% increase year-over-year.
- Cytek Biosciences, Inc. revenue for the twelve months ending March 31, 2026 was 183.5 M, a 3.92% decrease year-over-year.
- Cytek Biosciences, Inc. annual revenue for 2025 was 201.5 M, a 0.52% increase from 2024.
- Cytek Biosciences, Inc. annual revenue for 2024 was 200.5 M, a 3.85% increase from 2023.
- Cytek Biosciences, Inc. annual revenue for 2023 was 193.0 M, a 17.67% increase from 2022.
- Cytek Biosciences, Inc. annual revenue for 2022 was 164.0 M.
Cytek Biosciences, Inc. (CTKB) — Frequently Asked Questions
Cytek Biosciences, Inc. (CTKB) is a publicly traded US company. It has a market capitalization of $514M. In fiscal 2025 it reported revenue of $201M and net income of -$67M. Explore CTKB's stock price, financial statements, earnings history, margins and key ratios below.
What is Cytek Biosciences, Inc.'s market cap?
Cytek Biosciences, Inc. (CTKB) has a market capitalization of $514M.
What is the CTKB stock price?
CTKB trades at $4.02 (-0.74% on the day).
How much revenue does Cytek Biosciences, Inc. make?
Cytek Biosciences, Inc. reported revenue of $201M in fiscal 2025.
Is CTKB profitable?
In fiscal 2025, Cytek Biosciences, Inc. reported net income of -$67M.